A

Agenus

D
AGEN
USD
-0.275
(-6.5243%)
Market Closed
19,691.00
Volume
-8.34
EPS
-
Div Yield
-0.353680
P/E
84,993,447.54
Market Cap
Today
-6.5243%
1 Week
-6.413%
1 Month
-15.086%
6 Months
-67.167%
12 Months
-75.958%
Year To Date
-76.236%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
S
SGEN
(%)
USD
F
FATE
-0.24
(-8.6022%)
USD
O
ONCY
-0.09
(-7.6923%)
USD
P
PRTA
-0.16
(-0.907%)
USD
G
GNFT
0.28
(5.045%)
USD
V
VYGR
-0.18
(-2.4759%)
USD
C
CRVS
-0.74
(-7.7568%)
USD

Title:
Agenus

Sector:
Healthcare
Industry:
Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Do you need help or have a question?
Contact Us